MDM4 and retinoblastoma: New classes of small molecule MDM2/MDM4 inhibitors are being evaluated in Phase I/II studies in combination with broad-spectrum and targeted therapies; one of these is a trial in pediatric cancer including retinoblastoma (121, 124).